Macrophages: An elusive yet emerging therapeutic target of atherosclerosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Macrophages are central to the initiation and progression of atherosclerosis and thus can be very appropriate targets for therapy. Cell adhesion molecules mediating monocytes recruitment to the endothelium are attractive therapy targets and their inhibitors are in clinical trials. Macrophage scavenger receptors like SR‐A and CD‐36 mediate foam cell formation by facilitating the uptake of modified lipids. Peroxisome proliferator‐activated receptors (PPAR), liver X receptor (LXR)‐mediated signaling, mitogen‐activated protein kinase (MAPK) induced phosphorylation events seem to play an important role in this phenomenon. Proteins affecting macrophage cholesterol metabolism and transport, including ATP‐binding cassette (ABC) A1, ABCG1, acyl‐CoA:cholesterol acyltransferase (ACAT), apolipoprotein A‐1 (ApoA‐1), neutral cholesteryl ester hydrolase (NCEH) also regulate foam cell formation and are being developed as therapeutic targets by many pharmaceutical companies. Macrophage proliferation and apoptosis are important events controlling inflammatory response, plaque vulnerability, and destabilization. Free cholesterol (FC) activates the macrophage endoplasmic reticulum (ER) stress pathway and apoptosis. Free radicals and nitric oxide also modulate macrophage foam cell formation and apoptosis. Various antioxidants like AGI‐1067 and BO‐653 are in clinical trials for atherosclerosis treatment. Macrophage matrix metalloproteinase's (MMP's) play a significant role in weakening and rupture of plaques. Efforts are on to develop isoform specific MMP inhibitor. CD‐14, MMP‐3, ABCA1, Toll‐like receptor‐4 (TLR‐4), lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1), arachidonate lipoxygenase‐15 (ALOX‐15), and Connexin37 polymorphisms and macrophage dysfunction signify their importance in atherosclerosis. Deciphering the role of macrophages in regulating dyslipidemia and inflammation during atherosclerosis is important for developing them as therapeutic targets. © 2007 Wiley Periodicals, Inc. Med Res Rev, 28, No. 4, 483–544, 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965 · cited 1×
“The MCP-1 receptor, CCR-2 knockouts also show reduced atherosclerosis.(57) It”
BackgroundNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 2×
“Here it was demonstrated that there is reverse transit of macrophages from the plaque to the blood signifying the importance of macrophage emigration in atherosclerosis treatment.483 Plaque regression has been demonstrated in humans treated with simvastatin484 and infusion of apolipoprotein A-1 (ApoA-1) Milano.485 Ide…”
BackgroundMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687 · cited 1×
“Lossof-function mutations in the ABCA1 gene cause Tangier disease, a rare genetic disorder with accumulation of lipid-laden macrophages in tissues, absence of plasma HDL, and an increased risk of CAD in some families.(504,505) A study done to see the reported association between the 565C>Tpolymorphism and atherosclero…”
BackgroundActivation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233
Cited by
MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets
Muslin, A. J. (2008) · Clinical Science · doi:10.1042/cs20070430 · Cited by 494
Liposomes in ultrasonic drug and gene delivery
Huang, S.-L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.003 · Cited by 339
Atherosclerosis as an Inflammatory Disease
Tuttolomondo, A., Di Raimondo, D., Pecoraro, R., Arnao, V., Pinto, A., & Licata, G. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802481237 · Cited by 257
SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis
Stein, S., Lohmann, C., Schäfer, N., Hofmann, J., Rohrer, L., Besler, C., Rothgiesser, K. M., Becher, B., Hottiger, M. O., Borén, J., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq107 · Cited by 188
Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149
Ren, K., Li, H., Zhou, H.-F., Liang, Y., Tong, M., Chen, L., Zheng, X.-L., & Zhao, G.-J. (2019) · Aging · doi:10.18632/aging.102498 · Cited by 83
Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-6
Watanabe, R., Watanabe, H., Takahashi, Y., Kojima, M., Konii, H., Watanabe, K., Shirai, R., Sato, K., Matsuyama, T.-A., Ishibashi-Ueda, H., et al. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.07.008 · Cited by 36
Metadata
- Authors
- Tiwari, R. L., Singh, V., & Barthwal, M. K.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2007-11-14
- Volume
- 28
- Issue
- 4
- Pages
- 483-544
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2036746876
- Cited by
- 153
- References
- 37
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.